

Ordering Information

Part number OD376	Sample type Whole blood
Description VISITECT CD4 Advanced Disease	CE-marked Yes
Tests per kit 25	



© 2019 Omega Diagnostics Limited
VISITECT is a registered trademark of Omega Diagnostics Limited in the UK and other jurisdictions.

Omega Diagnostics Ltd

Omega House, Hillfoots Business Village,
Alva, FK12 5DQ, Scotland, United Kingdom

T +44 (0) 1259 763030
E odl@omegadiagnostics.co.uk
W www.omegadiagnostics.com

A subsidiary of Omega Diagnostics Group PLC
AN ISO 9001 AND ISO 13485 CERTIFIED COMPANY

V1 APRIL 2019
14376



VISITECT® CD4 Advanced Disease

Supporting the identification of advanced
disease in people living with HIV



Global **challenges** • Global **solutions**



VISITECT® CD4 Advanced Disease supports the identification of advanced disease in people living with HIV

VISITECT® CD4 Advanced Disease is a unique, instrument-free, rapid and disposable CD4 test.

CD4 remains the best measurement of a patient's immune and clinical status, identifying those at risk of


opportunistic infections (OI), and supporting diagnostic decision-making, particularly for patients living with advanced HIV disease.¹

VISITECT® CD4 Advanced Disease is a rapid, semi-quantitative lateral flow assay for the estimation of



CD4 protein on the surface of CD4+ T cells in human whole blood that indicates whether the level is above or below 200 cells/μL. It can be used in decentralised settings at the point-of-care or primary healthcare level.

Performance data with capillary samples²

Sensitivity



Specificity



VISITECT® CD4 Advanced Disease **benefits** people living with HIV and healthcare providers

Accelerate clinical disease management
Faster decision-making, reduce burden on healthcare workers


Reduce patient loss to follow-up
Improve patient retention

Test anywhere, anytime
Convenient, disposable and read by eye

Reduce costs
Zero investment in equipment, no sample transport required

Improve patient outcomes
Patients with advanced HIV disease targeted for OI investigations earlier

Test interpretation



BELOW REFERENCE BELOW REFERENCE ABOVE REFERENCE

¹N Ford et al. The evolving role of CD4 cell counts in HIV care. *Curr Opin HIV AIDS*. 2017; 12: 123-128

²VISITECT® CD4 Advanced Disease performance compared to flow cytometry in two studies conducted in India (n=144) and Zimbabwe (n=145) using finger-prick blood. 95% Confidence Intervals.